hers glp-1 injection reviews Hims & Hers Will No

10.1371/journal.pone.0119034 124 RosenstockJ.FriasJ.JastreboffA

For starters, the drug may not outperform the latest GLP-1 therapies out there

There is no additional cost for split shipments.

Phase 2 trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) reported mean weight reductions of up to approximately 24% over 48 weeks in adults with obesity notably higher than results seen with currently approved agents

The Performance plan is higher roughly 700 calories and 52g protein which may be too much volume for GLP-1 patients with suppressed appetite

Injectable vs oral compounded semaglutide, which is cheaper and which has evidence